StemCells, Inc. Reports Positive Interim Data From Spinal Cord Injury Trial
September 3, 2012 - (StemCells, Inc.) - "StemCells, Inc. today announced that interim six-month data from the first patient cohort in the Company's Phase I/II clinical trial of its proprietary HuCNS-SC® product candidate (purified human neural stem cells) for chronic spinal cord injury continues to demonstrate a favorable safety profile, and shows considerable gains in sensory function in two of the three patients compared to pre-transplant baselines." Read Full Article
